Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202216225 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Hilal Kalkan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli, Italy. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Duchenne Parent Project, Sentinelle Nord.
Abstract (Originalsprache)
Nothing is known about the potential implication of gut microbiota in skeletal muscle disorders. Here, we provide evidence that fecal microbiota composition along with circulating levels of short‐chain fatty acids (SCFAs) and related metabolites are altered in the mdx mouse model of Duchenne muscular dystrophy (DMD) compared with healthy controls. Supplementation with sodium butyrate (NaB) in mdx mice rescued muscle strength and autophagy, and prevented inflammation associated with excessive endocannabinoid signaling at CB1 receptors to the same extent as deflazacort (DFZ), the standard palliative care for DMD. In LPS‐stimulated C2C12 myoblasts, NaB reduces inflammation, promotes autophagy, and prevents dysregulation of microRNAs targeting the endocannabinoid CB1 receptor gene, in a manner depending on the activation of GPR109A and PPARγ receptors. In sum, we propose a novel disease‐modifying approach in DMD that may have benefits also in other muscular dystrophies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli, Italy.
- Department of Pharmacy, University Federico II of Naples, Italy.
- Institut Universitaire de Cardiologie et de Pneumologie de Québec and Institut Sur la Nutrition et Les Aliments Fonctionnels, Centre NUTRISS, Université Laval, Quebec City, QC, Canada.
- Unit of Muscle Research, Experimental and Clinical Research Center Charité Universitätsmedizin and Max Delbrück Research Center, Berlin, Germany.
- Department of Agricultural Sciences, University of Naples Federico II, Portici, Italy.
ORCID-Profile: Debora Paris, Elisabetta Panza, Claudia Moriello, Fabiana Piscitelli, Raffaele Capasso, Andrea Motta, Roberto Russo, Vincenzo Di Marzo, Fabio Arturo Iannotti
Förderung
- Duchenne Parent Project
- Sentinelle Nord
Zitieren
APA
Kalkan, H., Pagano, E., Paris, D., Panza, E., Cuozzo, M., Moriello, C., Piscitelli, F., Abolghasemi, A., Gazzerro, E., Silvestri, C., Capasso, R., Motta, A., Russo, R., Di Marzo, V., & Iannotti, F. A. (2023). Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216225
Vancouver
Kalkan H, Pagano E, Paris D, Panza E, Cuozzo M, Moriello C, et al. Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202216225
BibTeX
@article{Kalkan2023,
author = {Kalkan, Hilal and Pagano, Ester and Paris, Debora and Panza, Elisabetta and Cuozzo, Mariarosaria and Moriello, Claudia and Piscitelli, Fabiana and Abolghasemi, Armita and Gazzerro, Elisabetta and Silvestri, Cristoforo and Capasso, Raffaele and Motta, Andrea and Russo, Roberto and Di Marzo, Vincenzo and Iannotti, Fabio Arturo},
title = {Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202216225}
}
EUVIMED